利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.034 秒)

    Methods for improving cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves
    1.
    发明申请
    Methods for improving cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves 审中-公开
    通过冲击波改善心血管和神经系统疾病患者的细胞治疗和组织再生的方法

    公开(公告)号：US20060246044A1

    公开(公告)日：2006-11-02

    申请号：US11304865

    申请日：2005-12-15

    申请人： Andreas Lutz ,  Harald Eizenhofer ,  Andreas Zeiher ,  Stefanie Dimmeler ,  Christopher Heeschen ,  Alexandra Aicher

    发明人： Andreas Lutz ,  Harald Eizenhofer ,  Andreas Zeiher ,  Stefanie Dimmeler ,  Christopher Heeschen ,  Alexandra Aicher

    IPC分类号： A61K48/00 ,  A61H1/00 ,  C12N15/09

    CPC分类号： A61H23/008 ,  A61B17/22004 ,  A61B2017/00247 ,  A61B2018/00392 ,  A61K35/44 ,  A61K38/1866 ,  A61K38/195 ,  A61K2300/00

    摘要： Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.

    摘要翻译： 通过用冲击波治疗患者的组织和/或向患者施用治疗有效量的干细胞和/或祖细胞来改善患有心血管或神经疾病的患者的细胞治疗和组织再生。 这种治疗增加化学引诱物的表达，促血管生成因子和促生存因子。 化学引诱物可以是例如血管内皮生长因子（VEGF）或基质细胞衍生因子1（SDF-1）。 例如，经处理的组织可以位于患者的心脏或患者的骨骼肌中，冲击波可以是体外冲击波（ESW）或体内冲击波。 心血管疾病可能有缺血性或非缺血性病因。 例如，心血管疾病可以是心肌梗塞，缺血性心肌病或扩张型心肌病。 例如，神经系统疾病可以是周围神经病变或神经性疼痛。

    In Vitro Method for the Diagnosis of Cardiovascular Functionality of Bone Marrow-Precursor Cells (Bmp) and/or Circulation Precursor Cells Derived from Blood (Bdp)
    3.
    发明申请
    In Vitro Method for the Diagnosis of Cardiovascular Functionality of Bone Marrow-Precursor Cells (Bmp) and/or Circulation Precursor Cells Derived from Blood (Bdp) 有权
    用于诊断来自血液（Bdp）的骨髓前体细胞（Bmp）和/或循环前体细胞的心血管功能的体外方法

    公开(公告)号：US20070274959A1

    公开(公告)日：2007-11-29

    申请号：US10574380

    申请日：2004-10-13

    申请人： Andreas Zeiher ,  Christopher Heeschen ,  Stefanie Dimmeler

    发明人： Andreas Zeiher ,  Christopher Heeschen ,  Stefanie Dimmeler

    IPC分类号： A61K35/14 ,  G01N33/567

    CPC分类号： G01N33/56966 ,  A61K2035/124 ,  G01N33/5005 ,  G01N2333/70589 ,  G01N2333/70596 ,  G01N2333/71 ,  G01N2333/755

    摘要： The present invention relates to an in vitro method for the analysis of a sample from a mammal in connection with cardiovascular diseases, wherein the method comprises the following steps: a) isolating of bone marrow-precursor cells (BMPs) and/or blood-derived circulating precursor cells (BDPs) by means of cell specific surface markers, and b) detecting the cardiovascular functionality of the isolated BMPs and/or BDPs by means of a suitable migration assay. The method according to the invention can be employed as a kit in the context of the diagnosis and/or the prognosis of cardiovascular diseases, for the monitoring of their therapies and/or for a stratification for a prospective cell therapy with stem- and/or precursor cells in order to increase the perfusion of ischemic tissue or for a regeneration of tissue losses (e.g. heart insufficiency), respectively. In a further aspect, the present invention then relates to an in vitro method for isolating specific bone marrow-precursor cells by means of a suitable migration assay. According to the invention, these BMPs and/or BDPs can be used for the treatment of cardiovascular diseases, selected from the group consisting of stable coronary heart disease, acute coronary syndrome, acute myocardial infarction, chronic ischemic cardiomyopathy (ICMP), dilatative cardiomyopathy (DCM) or other causes for a heart insufficiency.

    摘要翻译： 本发明涉及用于分析哺乳动物与心血管疾病相关的样品的体外方法，其中所述方法包括以下步骤：a）分离骨髓前体细胞（BMP）和/或血液来源的 通过细胞特异性表面标志物循环前体细胞（BDP），和b）通过合适的迁移试验检测分离的BMP和/或BDP的心血管功能。 根据本发明的方法可以在心血管疾病的诊断和/或预后的背景下用作试剂盒，用于监测其疗法和/或用于具有茎和/或血管的前瞻性细胞治疗的分层， 为了增加缺血组织的灌注或组织损失（例如心脏功能不全）的再生，分别为前体细胞。 在另一方面，本发明涉及通过合适的迁移试验分离特异性骨髓前体细胞的体外方法。 根据本发明，这些BMP和/或BDP可用于治疗心血管疾病，其选自稳定性冠心病，急性冠状动脉综合征，急性心肌梗死，慢性缺血性心肌病（ICMP），扩张性心肌病 DCM）或心脏功能不全的其他原因。

    PIGF and FLT-1 as Prognostic Parameters for Cardiovascular Diseases
    8.
    发明申请
    PIGF and FLT-1 as Prognostic Parameters for Cardiovascular Diseases 审中-公开
    PIGF和FLT-1作为心血管疾病的预后参数

    公开(公告)号：US20090155827A1

    公开(公告)日：2009-06-18

    申请号：US11666164

    申请日：2005-10-25

    申请人： Andreas M. Zeiher ,  Christopher Heeschen ,  Stefanie Dimmeler

    发明人： Andreas M. Zeiher ,  Christopher Heeschen ,  Stefanie Dimmeler

    IPC分类号： C12Q1/48 ,  C12Q1/00

    CPC分类号： G01N33/74 ,  G01N33/6893 ,  G01N2800/324

    摘要： The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use.

    摘要翻译： 本发明涉及使用离体方法，其包括测定样品中的PlGF和sFlt-1用于具有动脉粥样硬化病因的血管疾病的诊断，风险分层和/或监测，特别是冠状动脉心脏病如不稳定 心绞痛或心肌梗塞，和/或用于估计发生这种疾病的可能性，以及用于鉴定可减轻心血管疾病风险的药物治疗的患者。 在方法（i）参考组的上两个三分位数中的[PlGF =高：sFlt-1 =低]和/或（ii）PlGF浓度的比例和下三分之一中的sFlt-1浓度 的参考集合，和（iii）高于PlGF参考值的PlGF结果，低于sFlt-1参考值的sFlt-1结果表明不良事件的概率升高。 本发明还涉及使用的方法。 本发明还涉及诊断试剂盒及其用途以及测定元件及其用途。

    MESOANGIOBLAST-LIKE CELL AS WELL AS METHODS AND USES RELATING THERETO
    9.
    发明申请
    MESOANGIOBLAST-LIKE CELL AS WELL AS METHODS AND USES RELATING THERETO 审中-公开
    MESOANGIOBLAST-LIKE CELL作为方法和使用相关的THERETO

    公开(公告)号：US20100068190A1

    公开(公告)日：2010-03-18

    申请号：US12491844

    申请日：2009-06-25

    申请人： Stefanie Dimmeler ,  Andreas Zeiher ,  Masamichi Koyanagi

    发明人： Stefanie Dimmeler ,  Andreas Zeiher ,  Masamichi Koyanagi

    IPC分类号： A61K35/12 ,  C12N5/00 ,  A61P9/00 ,  C12N15/00

    CPC分类号： A61K35/545 ,  A61K38/1833 ,  C12N5/0665 ,  C12N5/0692

    摘要： The present invention relates to a medicament comprising a mesoangioblast-like cell obtained from a subject, a method of isolating a mesoangioblast-like cell, a method of producing a mesoderm-derived cell using a mesoangioblast-like cell, the use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease and a method of converting the mesoangioblast-like cell into a pluripotent stem cell.

    摘要翻译： 本发明涉及一种药物，其包含从受试者获得的成细胞样细胞样细胞，分离中膜成血管细胞样细胞的方法，使用中胚细胞样细胞产生中胚层衍生细胞的方法，使用中胚性成纤维细胞样细胞， 用于制备用于治疗心血管疾病和/或缺血性疾病的药物的细胞样细胞，以及将成mesromanot母细胞转化为多能干细胞的方法。

    Endothelial cells as diagnostic instrument in cardiovascular diseases
    10.
    发明申请
    Endothelial cells as diagnostic instrument in cardiovascular diseases 审中-公开
    内皮细胞作为心血管疾病的诊断仪器

    公开(公告)号：US20050244897A1

    公开(公告)日：2005-11-03

    申请号：US10534150

    申请日：2003-11-17

    申请人： Andreas Zeiher ,  Stefanie Dimmeler ,  Lothar Rossig

    发明人： Andreas Zeiher ,  Stefanie Dimmeler ,  Lothar Rossig

    IPC分类号： G01N33/569 ,  G01N33/68 ,  G01N33/53 ,  G01N33/567

    CPC分类号： G01N33/6893 ,  G01N33/56966 ,  G01N2800/32

    摘要： The invention relates to a method for the immunocytological determination of apoptotic endothelial cells and/or endothelial precursor cells in samples such as, for example, peripheral blood, by means of, for example, throughflow cytometry or by means of a solid-phase immunoassay, as a diagnostic instrument in patients in whom a cardiovascular disease is either manifest or who carry the risk for the same and as an instrument by means of which the prevention and the therapeutic management of such a disease can be improved.

    摘要翻译： 本发明涉及通过例如流式细胞术或借助于固相免疫测定来免疫细胞测定样品例如外周血中的凋亡内皮细胞和/或内皮前体细胞的方法， 作为心血管疾病明显或具有相同风险的患者的诊断仪器，以及可以改善这种疾病的预防和治疗管理的仪器。